Establishment Labs (ESTA) vs TriMas (TRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Establishment Labs (ESTA) has outperformed TriMas (TRS) over the past year, gaining 51.1% versus a gain of 2.9%. Over five years, TRS leads with a +22.3% price change compared with -21.3% for ESTA. Establishment Labs is the larger company by market cap ($1.81 billion vs $1.38 billion), about 1.3 times the size.
On valuation, TriMas trades at a lower forward P/E (18.1x vs 1010.2x for Establishment Labs). TriMas pays a dividend yielding 0.42%, while Establishment Labs does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESTA | TRS |
|---|---|---|
| Share price | $60.61 | $38.44 |
| Market cap | $1.81B | $1.38B |
| 1-day change | -5.07% | +0.50% |
| YTD return | -16.84% | +8.43% |
| 1-year return | +51.07% | +2.89% |
| 5-year return | -21.29% | +22.30% |
| P/E ratio (TTM) | — | 15.63 |
| Forward P/E | — | 18.06 |
| EPS (TTM) | $-1.30 | $2.46 |
| Dividend yield | 0.00% | 0.42% |
| Annual dividend | $0.00 | $0.16 |
| Revenue (latest FY) | $211.08M | — |
| Revenue growth (YoY) | +27.14% | — |
| Net income (latest FY) | $-51.06M | — |
| Gross margin | 69.32% | — |
| Operating margin | -18.48% | — |
| Net margin | -24.19% | — |
| 52-week high | $97.59 | $45.43 |
| 52-week low | $38.38 | $30.43 |
| Distance from 52-week high | -37.89% | -15.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +69.02% | +17.07% |
| Average volume | 423.12K | 366.31K |
| Shares outstanding | 29.80M | 35.87M |
| Employees | 1,004 | 2,500 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESTA has outperformed TRS by 48.2 percentage points over the past year.
- The two companies sit in different sectors: Establishment Labs in Health Care and TriMas in Industrials.
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Health Care · Industrial Specialties · 1,004 employees
About TriMas
TRS stock →TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace and defense, and industrial markets worldwide. The company operates through Packaging and Specialty Products segments.
Industrials · Industrial Specialties · 2,500 employees
ESTA vs TRS FAQ
Which is bigger, Establishment Labs or TriMas?
Establishment Labs (ESTA) is larger, with a market capitalization of $1.81B compared with $1.38B for TriMas (TRS).
Which stock has performed better over the past year, ESTA or TRS?
ESTA returned +51.07% over the past 12 months, compared with +2.89% for TRS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Establishment Labs or TriMas?
TriMas pays a dividend yielding 0.42%, while Establishment Labs does not currently pay a regular dividend.
Are Establishment Labs and TriMas in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.